Target intelligence / Profile preview

Cordon-bleu WH2 repeat protein (COBL)

Target
COBL
Molecular classification
Actin nucleator, Cytoskeletal protein, Microfilament-associated protein, WH2 domain-containing protein, Other (not a receptor, enzyme, transporter, ion channel, transcription factor, etc.)
01

Overview

Cordon-bleu WH2 repeat protein (COBL) is a multifunctional actin regulatory protein containing three C-terminal WH2 (Wiskott-Aldrich syndrome protein homology 2) domains[1][2][3][4]. COBL orchestrates actin nucleation, filament severing, and regulation of dynamic actin structures essential for numerous morphogenetic and cellular processes. In neurons, COBL drives dendritic arborization and neuromorphogenesis; in epithelial cells, it localizes to the basal region of microvilli, regulating their length and assembling specialized actin-based protrusions. It interacts with partners such as syndapin and BAR domain-containing proteins. The protein is crucial for brush border microvilli development, neural tube closure in embryogenesis, and the organization of cellular protrusions. Its core molecular property is catalyzing the generation and remodeling of unbranched actin filaments; however, it is not known to be a direct therapeutic target nor a major player in disease pathogenesis[1][2][3][4].

Other names
Protein cordon-bleuCOBLKIAA0633COBL_HUMANCobl protein, human
02

Mechanism of action

Not applicable; COBL is not targeted by any drugs. Its mechanism in cell biology involves actin nucleation/severing via WH2 domains and interaction with BAR domain proteins (such as syndapin, SNX9, ASAP1)

03

Biological functions

Actin nucleation and remodelingRegulation of brush border microvilli length and assemblyRegulation of dendritic arbor and neuronal morphologyNeural tube closure and morphogenetic processes during developmentOrganization of specialized actin-based membrane protrusionsSevering actin filaments (via WH2 domains)
04

Disease associations

Other (not currently implicated as a central mediator in major diseases like cancer, inflammation, neurodegeneration, or cardiovascular disease; primarily studied in development and morphogenesis)Disruption can affect neural tube closure and morphogenesis, but no known direct disease indications as a therapeutic target
05

Safety considerations

None reported. There are no notable safety concerns or therapeutic challenges directly related to COBL, as it is not a pharmacological target
06

Interacting drugs

None currently known. There are no approved or experimental drugs that directly target COBL as a mechanism of action
07

Biomarkers

None. COBL is not widely used as a biomarker for patient selection or therapeutic monitoring

Beyond the preview

Go deeper on Cordon-bleu WH2 repeat protein (COBL).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cordon-bleu WH2 repeat protein (COBL).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call